CN113350343A - Application of dextro-chiral chloroquine phosphate in preparing medicine for treating coronavirus - Google Patents
Application of dextro-chiral chloroquine phosphate in preparing medicine for treating coronavirus Download PDFInfo
- Publication number
- CN113350343A CN113350343A CN202010321967.5A CN202010321967A CN113350343A CN 113350343 A CN113350343 A CN 113350343A CN 202010321967 A CN202010321967 A CN 202010321967A CN 113350343 A CN113350343 A CN 113350343A
- Authority
- CN
- China
- Prior art keywords
- chloroquine
- chiral
- phosphate
- dextro
- chloroquine phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960002328 chloroquine phosphate Drugs 0.000 title claims abstract description 39
- 239000003814 drug Substances 0.000 title claims abstract description 28
- AEUAEICGCMSYCQ-UHFFFAOYSA-N 4-n-(7-chloroquinolin-1-ium-4-yl)-1-n,1-n-diethylpentane-1,4-diamine;dihydrogen phosphate Chemical compound OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 AEUAEICGCMSYCQ-UHFFFAOYSA-N 0.000 title claims abstract description 27
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 claims description 16
- 229940079593 drug Drugs 0.000 abstract description 15
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 abstract description 12
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 abstract description 12
- 229960003677 chloroquine Drugs 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 5
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- 238000000338 in vitro Methods 0.000 abstract description 2
- 239000007787 solid Substances 0.000 description 42
- 238000003756 stirring Methods 0.000 description 33
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- 238000001914 filtration Methods 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 238000001816 cooling Methods 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 238000001035 drying Methods 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000013078 crystal Substances 0.000 description 10
- 238000010438 heat treatment Methods 0.000 description 10
- 238000004296 chiral HPLC Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 229910019142 PO4 Inorganic materials 0.000 description 7
- 230000000120 cytopathologic effect Effects 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 235000021317 phosphate Nutrition 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 230000005587 bubbling Effects 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- DVWQNBIUTWDZMW-UHFFFAOYSA-N 1-naphthalen-1-ylnaphthalen-2-ol Chemical compound C1=CC=C2C(C3=C4C=CC=CC4=CC=C3O)=CC=CC2=C1 DVWQNBIUTWDZMW-UHFFFAOYSA-N 0.000 description 4
- 241001678559 COVID-19 virus Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 239000002932 luster Substances 0.000 description 4
- 239000012452 mother liquor Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 231100000491 EC50 Toxicity 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 231100000645 Reed–Muench method Toxicity 0.000 description 2
- 239000003907 antipyretic analgesic agent Substances 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- -1 chloroquine phosphates Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of dextrorotatory chiral chloroquine phosphate in preparing a medicament for treating coronavirus. The inventor finds that in vitro cell experiments, the dextro-chiral chloroquine phosphate has better effect on resisting new coronavirus than the currently applied chloroquine phosphate, and under the condition that the inhibition rate (78.33%) is the same, the drug concentration of the dextro-chiral chloroquine phosphate is 3.75 mug/mL, and the drug concentration of the racemic chloroquine is 6.25 mug/mL. The invention provides a new approach for treating coronavirus.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to application of dextrorotatory chiral chloroquine phosphate in preparation of a medicine for treating coronavirus.
Background
Chloroquine phosphate is an old medicine which has been applied as early as the three and four decades of the last century and is mainly used for treating malaria. Recent studies show that chloroquine has a certain inhibitory effect on viruses (2019-nCoV) causing the novel coronavirus pneumonia COVID-19.
The side chain of the chloroquine contains a chiral carbon, and the chloroquine in various dosage forms in clinical application at present is a racemate. The existing research shows that the chiral structure of some medicines has close relation with the biological activity thereof, for example, ibuprofen antipyretic analgesic commonly used in daily life mainly plays a role in S configuration, and R configuration of the ibuprofen antipyretic analgesic has no activity at all. For chloroquine, no related report of chiral chloroquine in resisting coronavirus exists at present.
Disclosure of Invention
The invention aims to overcome the defects in the prior art and provides the application of dextrorotatory chiral chloroquine phosphate in preparing a medicament for treating coronavirus.
The purpose of the invention is realized by the following technical scheme: the application of the dextro-chiral chloroquine phosphate in preparing the medicine for treating the coronavirus is based on the discovery of the inventor of the invention that the dextro-chiral chloroquine phosphate has obvious inhibiting effect on the novel coronavirus (SARS-CoV-2) in vitro cell experiments, and compared with the racemic chloroquine phosphate, the dextro-chiral chloroquine phosphate can inhibit the novel coronavirus at a lower concentration.
The structural formula of the dextrorotatory chiral chloroquine phosphate S- (+) -chloroquine phosphate is as follows:
the coronavirus is preferably a novel coronavirus (2019-ncov, also known as SARS-CoV-2).
The concentration of the dextro-chloroquine phosphate is preferably more than 1.88 mu g/mL; more preferably 3.75 to 60. mu.g/mL.
Compared with the prior art, the invention has the following advantages and effects:
the inventor finds that the dextro-chiral chloroquine phosphate has better effect on resisting new coronavirus than the currently applied chloroquine phosphate, and under the condition of the same inhibition rate (78.33%), the drug concentration of the dextro-chiral chloroquine phosphate is 3.75 mu g/mL, and the drug concentration of the racemic chloroquine is 6.25 mu g/mL.
Drawings
FIG. 1 is a graph showing the results of the test of the pharmacological effects of dexchloroquine phosphate on the novel coronavirus.
FIG. 2 is a graph showing the results of the measurement of the pharmacological effects of racemic chloroquine phosphate on the novel coronavirus.
Detailed Description
The present invention will be described in further detail with reference to examples and drawings, but the embodiments of the present invention are not limited thereto.
EXAMPLE 1 preparation of chiral chloroquine phosphate
(1) Preparation of S- (+) -chloroquine binaphthol phosphate
Taking 8.3g chloroquine racemate, adding 9.7g of (S) - (+) -binaphthol phosphate, adding 90g of isopropanol and 30g of acetone, heating and dissolving at 70 ℃, keeping the temperature for 1h, stirring and cooling to room temperature, cooling to 0-4 ℃, standing for 18h, separating out crystals, filtering, draining, storing filtrate as R-rich mother liquor, obtaining a light yellow solid filter cake, and drying at 60 ℃ to obtain 11.8g of S- (+) -chloroquine binaphthol phosphate.
(2) Recrystallization
Adding 11.8g (17.7mmol) of the solid obtained in the step (1) into 75g of isopropanol and 25g of acetone, heating to dissolve at 70 ℃, slowly stirring to room temperature, cooling to 0-4 ℃, standing for 6 hours, separating out large-particle crystals, filtering, draining to obtain a loose solid with luster, and drying at 60 ℃ to obtain 8.6g of the solid.
(3) Preparation of S- (+) -chloroquine and recovery of (S) - (+) -binaphthol phosphate
Adding 15g methanol and 10g sodium hydroxide solution with the concentration of 30 percent by mass into 8.6g (12.9mmol) of the solid obtained in the step (2), stirring for 1h, adding 80ml dichloromethane and 80ml water, stirring, separating out a large amount of solid with good crystal form, filtering to obtain wet 10.2g white crystalline solid which is released (S) - (+) -binaphthol phosphate sodium salt, separating the phase of the filtrate, back-extracting the aqueous phase with 60ml dichloromethane, washing the organic phase with 60ml 3 water, combining the organic phases, adding anhydrous sodium sulfate, stirring and drying for 1h, filtering, distilling and recovering the solvent at normal pressure,evaporating to dryness at 90 deg.C under 10kPa under reduced pressure until no bubbling occurs to obtain 3.9g pale yellow oily substance, cooling to obtain yellow solid, which is S- (+) -chloroquine, and analyzing enantioselectivity of product by chiral HPLC, wherein ee value is 99.6%; [ alpha ] to]24 D＝+107.8°(c＝1,EtOH)。
(4) Preparation of S- (+) -chloroquine phosphate
Taking 3.2g of S- (+) -chloroquine prepared in the step (3), adding 60g of ethanol, heating and stirring at 70 ℃ for dissolving, adding 4.2g of phosphoric acid with the concentration of 50% by mass, immediately separating out a white solid, keeping the temperature and stirring for 1h, stirring and cooling to 10 ℃, filtering, pumping out, and drying in vacuum at 80 ℃ to obtain 4.7g of white solid which is S- (+) -chloroquine phosphate, wherein the product enantioselectivity is analyzed by chiral HPLC, and the ee value is 99.5%; [ alpha ] to]24 D＝+86.7°(c＝1,H2O)。
(5) Preparation of R- (-) -chloroquine
Adding 7.2g of sodium hydroxide solution with the concentration of 30% by mass into the R-enriched mother liquor obtained in the step (1), distilling and recovering the solvent at normal pressure, adding 80ml of dichloromethane and 80ml of water into a distillation residue, stirring, carrying out phase separation, carrying out back extraction on an aqueous phase by using 60ml of dichloromethane, washing an organic phase by using 60ml of 3 water, combining organic phases, adding anhydrous sodium sulfate and active carbon, stirring and drying for 1h, filtering, distilling and recovering the solvent from the filtrate at normal pressure, carrying out reduced pressure distillation at 90 ℃ under 10kPa, evaporating until bubbling does not occur to obtain 3.8g of light yellow oily matter, wherein the product is a crude product of R- (-) -chloroquine, and the enantioselectivity of the product is analyzed by chiral HPLC, and the ee value is 53%; [ alpha ] to]24 D＝-58.1°(c＝ 1,EtOH)。
(6) Refining of R- (-) -chloroquine and recovery of (R) - (-) -binaphthol phosphate
Adding 4.1g of (R) - (-) -binaphthol phosphate into the crude product of the R- (-) -chloroquine obtained in the step (5), adding 40g of isopropanol, 10g of acetone and 2g of water, heating and dissolving at 60 ℃, keeping the temperature for 1h, stirring and cooling to room temperature, cooling to 0-4 ℃, standing for 12h, separating out crystals, filtering, draining to obtain a loose solid with luster, adding 10g of methanol and 5g of sodium hydroxide solution with the concentration of 30 percent by mass into the loose solid, stirring for 1h, adding 60ml of dichloromethane and 80ml of water, stirring, separating out a large amount of solid with good crystal forms, and filtering to obtain 4.1g of wet white crystalline solid which is released as a white crystalline solidThe (R) - (-) -binaphthol phosphate sodium salt is subjected to phase separation, the water phase is subjected to back extraction by 70ml of dichloromethane, the organic phase is washed by 50ml of 3 water, the organic phases are combined, anhydrous sodium sulfate is added, stirring and drying are carried out for 1h, filtering is carried out, the solvent is recovered by normal pressure distillation, reduced pressure evaporation is carried out at 90 ℃ and 10kPa is carried out, 2.7g of light yellow oily matter is obtained by evaporation until no bubbling occurs, the yellow oily matter is cooled to be yellow solid, the solid is R- (-) -chloroquine, the enantioselectivity of the product is analyzed by chiral HPLC, and the ee value is 99%; [ alpha ] to]24 D＝-107.0°(c＝1,EtOH)。
(7) Preparation of R- (-) -chloroquine phosphate
Taking 1.6g of R- (-) -chloroquine prepared in the step (6), adding 10g of methanol and 20g of isopropanol, heating and stirring at 70 ℃ for dissolving, adding 1.2g of phosphoric acid with the concentration of 85% by mass, immediately precipitating a white solid, keeping the temperature and stirring for 1h, stirring and cooling to 10 ℃, filtering, draining, and drying in vacuum at 80 ℃ to obtain 2.2g of the white solid which is the R- (-) -chloroquine phosphate, wherein the product enantioselectivity is analyzed by manual HPLC, and the ee value is 99%; [ alpha ] to]24 D＝-86.0°(c＝1,H2O)。
EXAMPLE 2 preparation of chiral chloroquine phosphate
(1) Preparation of R- (-) -chloroquine binaphthol phosphate
Taking 4.6g chloroquine racemate (CASNO.54-05-7), adding 5.4g of (R) - (-) -binaphthol phosphate, adding 50g of isopropanol and 16g of acetone, heating and dissolving at 60 ℃, keeping the temperature for 1h, stirring and cooling to room temperature, cooling to 0-4 ℃, standing for 12h, precipitating crystals, filtering, draining, storing the filtrate as S-enriched mother liquor, taking a filter cake as a light yellow solid, and drying at 60 ℃ to obtain 6.2g of solid, wherein the solid is R- (-) -chloroquine binaphthol phosphate.
(2) Recrystallization
Adding 30g of isopropanol and 9g of acetone into 6.2g of the solid obtained in the step (1), heating and dissolving at 60 ℃, slowly stirring to room temperature, cooling to 0-4 ℃, standing for 6h, separating out large-particle crystals, filtering, draining to obtain a loose solid with luster, and drying at 60 ℃ to obtain 4.7g of solid.
(3) Preparation of R- (-) -chloroquine and recovery of (R) - (-) -binaphthol phosphate
Adding 10g of methanol and 7g of the solid obtained in the step (2) to 4.7g (7mmol) of the solid to a concentration of 20% by massStirring the sodium hydroxide solution for 1 hour, then adding 50ml of dichloromethane and 50ml of water, stirring, separating out a large amount of solid with good crystal form, filtering to obtain a wet white crystalline solid with the weight of 5.31g, wherein the solid is released (R) - (-) -binaphthol phosphate sodium salt, separating the filtrate, back-extracting the aqueous phase by using 40ml of dichloromethane, washing the organic phase by using 40ml of 3 water, combining the organic phases, adding anhydrous sodium sulfate, stirring and drying for 1 hour, filtering, distilling and recovering the solvent under normal pressure, evaporating to dryness under 10kPa at 90 ℃, evaporating to dryness under reduced pressure until no bubbling exists to obtain 2.1g of light yellow oily matter, cooling to obtain a yellow solid, wherein the solid is R- (-) -chloroquine, and the enantioselectivity of the product is analyzed by chiral HPLC, and the ee value is 99%; [ alpha ] to]24 D＝-107.1°(c＝1,EtOH)。
(4) Preparation of R- (-) -chloroquine phosphate
Taking 1.6g of R- (-) -chloroquine prepared in the step (3), adding 25g of ethanol, heating and stirring at 70 ℃ for dissolving, adding 1.2g of phosphoric acid with the concentration of 85% by mass, immediately separating out a white solid, keeping the temperature and stirring for 1h, stirring and cooling to 20 ℃, filtering, draining, and drying in vacuum at 80 ℃ to obtain 2.3g of white solid which is R- (-) -chloroquine phosphate, wherein the product enantioselectivity is analyzed by chiral HPLC, and the ee value is 99%; [ alpha ] to]24D＝-86.8°(c＝1,H2O)。
(5) Preparation of S- (+) -chloroquine
Adding 6g of sodium hydroxide solution with the concentration of 20% in mass into the S-enriched mother liquor obtained in the step (1), distilling and recovering the solvent at normal pressure, adding 40ml of dichloromethane and 40ml of water into the residue of distillation, stirring, carrying out phase separation, carrying out back extraction on the water phase by using 40ml of dichloromethane, washing the organic phase by using 40ml of 3 water, combining the organic phases, adding anhydrous sodium sulfate and active carbon, stirring and drying for 1h, filtering, distilling and recovering the solvent at normal pressure of the filtrate, evaporating to dryness at 90 ℃ and 10kPa under reduced pressure until bubbling does not occur to obtain 2.15g of light yellow oily matter, wherein the product is a crude product of S- (+) -chloroquine, and the enantioselectivity of the product is analyzed by chiral HPLC, and the ee value is 49%; [ alpha ] to]24 D＝+52.5°(c＝ 1,EtOH)。
(6) S- (+) -chloroquine refining and (S) - (+) -binaphthol phosphate recovery
Adding 2.3g of (S) - (+) -binaphthol phosphate into the S- (+) -chloroquine crude product obtained in the step (5), adding 20g of isopropanol and 7g of acetone, heating and dissolving at 60 ℃,keeping the temperature for 1h, stirring and cooling to room temperature, cooling to 0-4 ℃, standing for 12h, precipitating crystals, filtering, pumping to dryness to obtain a loose solid with luster, adding 7g of methanol and 5g of sodium hydroxide solution with the concentration of 20% by mass into the solid, stirring for 1h, adding 30ml of chloroform and 30ml of water, stirring to separate out a large amount of solid with good crystal forms, filtering to obtain a white crystalline solid with the wet weight of 2.31g, wherein the solid is released (S) - (+) -binaphthol phosphate sodium salt, separating the filtrate, back-extracting the aqueous phase with 30ml of chloroform, washing the organic phase with 30ml of 3 water, combining the organic phases, adding anhydrous sodium sulfate, stirring and drying for 1h, filtering, distilling under normal pressure to recover the solvent, evaporating to dryness at 90 ℃ under 10kPa under reduced pressure, steaming to obtain 1.5g of light yellow substance without bubbling, cooling to obtain a yellow solid, wherein the solid is S- (+) -chloroquine oily, the enantioselectivity of the product is analyzed by chiral HPLC, and the ee value is 98 percent; [ alpha ] to]24 D＝+104.9°(c＝1,EtOH)。
(7) Preparation of S- (+) -chloroquine phosphate
Taking 1g of S- (+) -chloroquine prepared in the step (6), adding 20g of ethanol, heating and stirring at 70 ℃ for dissolving, adding 0.72g of phosphoric acid with the concentration of 85% by mass, immediately separating out a white solid, keeping the temperature and stirring for 1h, stirring and cooling to 20 ℃, filtering, draining, and drying in vacuum at 80 ℃ to obtain 1.4g of the white solid which is S- (+) -chloroquine phosphate, wherein the enantioselectivity of the product is analyzed by chiral HPLC, and the ee value is 98%; [ alpha ] to]24 D＝+85.1°(c＝1,H2O)。
EXAMPLE 3 evaluation of Effect of dextrorotatory and racemic chloroquine phosphates on the resistance to novel coronavirus (SARS-COV-2) at cellular level
The experiment for evaluating the effect of a drug against the novel coronavirus (SARS-COV-2) at the cellular level was conducted by the Guangzhou respiratory health institute. Wherein the used cells are VeroE6 cells, and are preserved by a virus laboratory in the respiratory disease national key laboratory of Guangzhou respiratory health research institute; virus SARS-CoV-2, titer TCID50＝10-6100 μ L, stored at 80 ℃ in BSL-3 laboratory (respiratory disease national center laboratory high pathogenic microorganism research laboratory). Using a Virus titre of 100TCID50。
The dextro-chiral chloroquine is prepared according to the step (1) of the example 1
2.1 test drug antiviral Experimental procedures
(1) The tested drugs are:
table 1 drug name, experimental concentration and grouping
(2) Sterile 96-well culture plate, 100. mu.L of 2X 10 concentration per well5cells/mL VeroE6 cells, 37 ℃ and 5% CO2Culturing for 24 hours;
(3) adding 100TCID into culture plate experimental group and virus control group50Virus liquid 100 mul/well, 37 deg.C, 5% CO2Adsorbing for 2 hours by an incubator;
(4) after 2h, discarding the cell culture solution in the 96-well culture plate; diluting the tested medicine into each concentration in table 1, wherein each concentration is 3 multiple holes, and adding the liquid medicine into each hole at 100 mu L;
(5) simultaneously setting a cell control, a blank control (a solvent control), a virus control (a negative control) and a positive drug control (chloroquine or Reidesvir);
(6) at 37 ℃ with 5% CO2Incubating in an incubator for 3-4 days;
(7) cytopathic effect (CPE) was observed under an optical microscope and the degree of cytopathic effect was recorded according to the following 6-point scale: "-" no lesions present; "±" means less than 10% cytopathic effect; "+" is about 25% of the cellular pathology; "+ +" indicates about 50% of cellular pathology; "+ + + +" indicates that about 75% of the cells are diseased: "+ ++" indicates that 75% or more of the lesions are diseased. The half maximal effective concentration (IC50) was calculated using the Reed-Muench method or GraphPadprism 5.0. Judging the drug effect standard: concentrations that inhibit viral CPE by 50% are considered effective concentrations.
(8) The experimental conditions are as follows: the experimental operations are all completed in a BSL-3 level biological safety laboratory.
2.2 Experimental results and analysis
The half maximal effective concentration (IC50) was calculated by observing cytopathic effect (CPE) and recording the results of the experiment, as shown in tables 2-3 and FIGS. 1-2, using the Reed-Muench method or GraphPadprism 5.0:
TABLE 2 results of the pharmacological effects of dexchloroquine phosphate against the novel coronavirus
| Drug concentration (μ g/mL) | Inhibition ratio (%) |
| 60 | 93.33±2.89 |
| 30 | 88.33±2.89 |
| 15 | 83.33±2.89 |
| 7.5 | 81.67±2.89 |
| 3.75 | 78.33±2.89 |
| 1.88 | 46.67±10.41 |
| 0.94 | 16.67±2.89 |
TABLE 3 results of the pharmacological effects of racemic chloroquine phosphate against novel coronaviruses
| Drug concentration (μ g/mL) | Inhibition ratio (%) |
| 25 | 91.67±2.89 |
| 12.5 | 86.67±2.89 |
| 6.25 | 78.33±2.89 |
| 3.13 | 56.67±2.89 |
| 1.56 | 26.67±2.89 |
| 0.78 | 6.67±2.89 |
The above experimental results show that: under the condition of the same inhibition rate (78.33%), the drug concentration of the dextrorotatory chiral chloroquine phosphate is 3.75 mug/mL, and the drug concentration of the racemic chloroquine is 6.25 mug/mL; the IC50 value of the dextro-chiral chloroquine phosphate is lower.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.
Claims (4)
1. Application of dextro-chiral chloroquine phosphate in preparing medicine for treating coronavirus.
2. The use of dextro-chiral chloroquine phosphate according to claim 1 for the preparation of a medicament for the treatment of coronavirus, wherein: the coronavirus is a novel coronavirus.
3. The use of dextro-chiral chloroquine phosphate according to claim 2 for the preparation of a medicament for the treatment of coronavirus, wherein: the concentration of the dextro-chloroquine phosphate is more than 1.88 mu g/mL.
4. The use of dextro-chiral chloroquine phosphate according to claim 3 for the preparation of a medicament for the treatment of coronavirus, wherein: the concentration of the dextro-chloroquine phosphate is 3.75-60 mu g/mL.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010150708 | 2020-03-06 | ||
| CN2020101507080 | 2020-03-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113350343A true CN113350343A (en) | 2021-09-07 |
Family
ID=77524376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010321967.5A Pending CN113350343A (en) | 2020-03-06 | 2020-04-22 | Application of dextro-chiral chloroquine phosphate in preparing medicine for treating coronavirus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113350343A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111732539A (en) * | 2020-07-23 | 2020-10-02 | 珠海润都制药股份有限公司 | Chloroquine phosphate enantiomer crystal form and preparation method thereof |
| CN113527201A (en) * | 2020-04-14 | 2021-10-22 | 瀚海新拓(杭州)生物医药有限公司 | Optically active chloroquine and hydroxychloroquine and analogs thereof, preparation method, composition and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5314894A (en) * | 1992-09-15 | 1994-05-24 | Sterling Winthrop Inc. | (S)-(+)-hydroxychloroquine |
| US6417177B1 (en) * | 1999-07-13 | 2002-07-09 | Alpha Research Group, Llc | Chloroquine derivatives for the treatment of Parkinson's disease |
| CN103347535A (en) * | 2010-12-02 | 2013-10-09 | 昂科利蒂克斯生物科技公司 | Liquid viral formulations |
| WO2015157223A1 (en) * | 2014-04-07 | 2015-10-15 | University Of Maryland, Baltimore | Methods of treating coronavirus infection |
-
2020
- 2020-04-22 CN CN202010321967.5A patent/CN113350343A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5314894A (en) * | 1992-09-15 | 1994-05-24 | Sterling Winthrop Inc. | (S)-(+)-hydroxychloroquine |
| US6417177B1 (en) * | 1999-07-13 | 2002-07-09 | Alpha Research Group, Llc | Chloroquine derivatives for the treatment of Parkinson's disease |
| CN103347535A (en) * | 2010-12-02 | 2013-10-09 | 昂科利蒂克斯生物科技公司 | Liquid viral formulations |
| WO2015157223A1 (en) * | 2014-04-07 | 2015-10-15 | University Of Maryland, Baltimore | Methods of treating coronavirus infection |
Non-Patent Citations (5)
| Title |
|---|
| GAO, JJ等: "Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies", 《BIOSCIENCE TRENDS》 * |
| PATRICK AUGUSTIJNS等: "Stereos elective Pharmacokinetic Properties of Chloroquine and De-Ethyl-Chloroquine in Humans", 《ORIGINAL RESEARCH ARTICLE》 * |
| 曾苏: "《手性药物与手性药理学》", 30 April 2002 * |
| 蒋荣海: "《药物化学基础》", 31 May 2001 * |
| 郭增军等: "《新药发现与筛选》", 31 January 2017, 西安交通大学出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113527201A (en) * | 2020-04-14 | 2021-10-22 | 瀚海新拓(杭州)生物医药有限公司 | Optically active chloroquine and hydroxychloroquine and analogs thereof, preparation method, composition and application thereof |
| CN111732539A (en) * | 2020-07-23 | 2020-10-02 | 珠海润都制药股份有限公司 | Chloroquine phosphate enantiomer crystal form and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113181339B (en) | Medicinal application of aldehyde compound | |
| CN113350343A (en) | Application of dextro-chiral chloroquine phosphate in preparing medicine for treating coronavirus | |
| CN108676067B (en) | A kind of noval chemical compound and preparation method thereof of pre- preventing HIV infection | |
| CN111471013B (en) | Mickura ammonium chloride and preparation method of injection thereof | |
| CN108947949B (en) | Anxiolytic deuterated compounds and medical application thereof | |
| CN109438371B (en) | Methylpyrazine derivative arginine hydrate | |
| CN113105425A (en) | Anti-inflammatory compound, preparation method and anti-inflammatory application thereof | |
| TWI384986B (en) | Maleic acid monosalt of antiviral agent and pharmaceutical composition containing the same | |
| CN113350344A (en) | Application of levorotatory chiral chloroquine phosphate in preparation of drugs for treating coronavirus | |
| EP2358369A1 (en) | Process for the preparation of substantially optically pure repaglinide and precursors thereof | |
| CN116120282B (en) | Compounds with EV71 and/or CVA16 virus inhibiting activity and application thereof | |
| CN101347412A (en) | Amifostine trihydrate crystal lyophilized preparation and method of preparing the same | |
| CN111138499B (en) | Anderson polyacid and application thereof in resisting ADV7 virus | |
| CN110724102B (en) | Polyphenol compound containing tetrahydropapaverine-3-carboxylic acid methyl ester and preparation method and application thereof | |
| CN111518040B (en) | Methylpyrazine derivative-piperazine eutectic | |
| CN1299813A (en) | N-substituted benzyl or phenyl aromatic amide compound and its use | |
| CN102336701A (en) | Carvedilol sulphate crystals, preparation method and application thereof in medicine | |
| CN102633796A (en) | New preparation method of sophora flavescens acid derivative | |
| CN107382944B (en) | Coumarin gossypol derivatives with anti-tumor activity and synthesis method thereof | |
| CN103848789B (en) | A kind of preparation method of Ivabradine | |
| CN112110865A (en) | Isonicotinamide acipimox cocrystal II and preparation method thereof | |
| CN112159395B (en) | 4-alanine substituted cytosine nucleoside compound and pharmaceutical application thereof | |
| CN110684066B (en) | Cytophosphocholine medicinal preparation and new application thereof in cerebral infarction acute-stage disturbance of consciousness | |
| CN111518098B (en) | Methylpyrazine derivative theophylline dihydrate | |
| CN110713471A (en) | Synthetic method of trimetazidine hydrochloride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210907 |